New hope for kids battling Tough-to-Treat tuberculosis

NCT ID NCT02906007

Summary

This study aimed to find safe and effective doses of the drug bedaquiline for children and adolescents with a hard-to-treat form of tuberculosis (TB) that resists standard antibiotics. It involved 54 young people, from infants to teens, some also living with HIV. Researchers carefully monitored how the children's bodies processed the drug and checked for side effects over 24 weeks of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS

    Cape Town, Western Cape, 7505, South Africa

  • Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS

    Port-au-Prince, HT-6110, Haiti

  • PHRU Matlosana CRS

    Klerksdorp, North West, 2574, South Africa

  • Sizwe CRS

    Johannesburg, Gauteng, South Africa

Conditions

Explore the condition pages connected to this study.